ライフサイエンスコーパス: nontreated

1 ine bone density, femurs were collected from nontreated, 1,25-dihydroxyvitamin D3-treated (50 ng/mous

2 s for treated (1905 mm(-6)/sec2 +/- 446) and nontreated (1437 mm(-6)/sec2 +/- 270) fibroid tissue at

3 MM when treated with VBMCP (treated, 47.1% v nontreated, 66.5% [P = .015]).

4 cantly more susceptible to Ad infection than nontreated A20 cells.

5 amyloid burden, respectively, compared with nontreated AD mice.

6 period, but remained elevated compared with nontreated adoptive transfer mice.

7 No severe vision loss was reported for the 7 nontreated AEs.

8 t age-related cognitive decline displayed in nontreated aged animals.

9 All nontreated allografts rejected within 5 to 8 days posttr

10 ns in the oxidation of ICHO to ICOOH in both nontreated and AgNO3-treated leaves, whereas CYP71B6 is

11 Groups of nontreated and CFA-preimmunized male C57BL/6J or C57BL/6

12 this cell line and further characterizes the nontreated and induced myocardial and endothelial phenot

13 nd hepatic microcirculation were compared in nontreated and interleukin-6 (IL-6)-treated steatotic is

14 Additionally, we found that both nontreated and pembrolizumab-treated iTregs were suppres

15 ls entered the CNS in numbers equivalent for nontreated and PLP(139-151) MAP-treated animals.

16 d metabolite profiling, their composition in nontreated and silver nitrate (AgNO3)-treated leaf tissu

17 Regional (treated/nontreated) and whole liver function and volume were det

18 + xenografts to approximately 30% of that in nontreated animals (from 34 +/- 9 [mean +/- SD] to 9.5 +

19 d ED1(+) macrophages (-52%) that occurred in nontreated animals after 6 hours of reloading.

20 ration, and ascites volume, were observed in nontreated animals and were significantly diminished by

21 ered to rats at 500, 50, 5, and 0.5 mg/kg/d; nontreated animals were used as controls.

22 Nontreated animals were used as the control (Group 1, n=

23 reased 5-HT levels were observed after MI in nontreated animals, but not in the group treated with cy

24 PVBF, 79% of baseline vs. 45% of baseline in nontreated animals, P < 0.05, ANOVA).

25 treated animals, and between FSH-treated and nontreated animals.

26 -cell depletion were similar for treated and nontreated animals.

27 fter AAD, 48% underwent surgery of initially nontreated aortic segments (42% of patients with type A

28 thout AAD, 11% required surgery on primarily nontreated aortic segments (5 of 6 patients experienced

29 auses of surgical interventions in primarily nontreated aortic segments after previous aortic repair

30 The need for surgery in primarily nontreated aortic segments is precipitated by an initial

31 In addition, the nontreated area showed amplitude and timing mfERG defici

32 In comparison with nontreated asthmatic mice, we observed that: (i) The bet

33 sured fluorescence intensity for treated and nontreated beads.

34 s was correlated with the DN:P ratio for the nontreated brain tumor group (P < .0001).

35 oup demonstrated higher DN:P ratios than the nontreated brain tumor group for number of doses less th

36 ual to 10 (P < .0001), whereas ratios in the nontreated brain tumor group were higher than those in t

37 eated C57BL/6 Ly5.2 BM cells were mixed with nontreated C57BL/6 Ly5.1 BM cells and used to reconstitu

38 ks in diazoxide-treated hearts compared with nontreated Ca2+ PD hearts.

39 tably, we show that these mutations occur in nontreated cancer cell lines and primary tumor specimens

40 ant lesion and most importantly a secondary, nontreated, cancer lesion.

41 act the chemical fingerprint compared to the nontreated Cannabis.

42 se-treated xenografts was much lower than in nontreated cartilage and the proportion of T lymphocytes

43 eline to 24 h, was greater in treated versus nontreated cases (p < 0.001).

44 L-1betaAb-treated CDs-HSD rats compared with nontreated CDs-HSD rats.

45 01) and higher GSIS (P < 0.05) compared with nontreated CDs-HSD rats.

46 germ agglutinin affinity chromatography from nontreated cells exhibited substantial ligand-induced ph

47 nobufagenin levels by 67% when compared with nontreated cells or cells transfected with nontargeting

48 enhancer, and no DNA looping was observed in nontreated cells or cells treated with each of the hormo

49 inocytes compared with the results seen with nontreated cells or cells treated with glutathione S-tra

50 Nontreated cells were used as controls.

51 Mixing of extract from nontreated cells with small amounts of extract of CPT-tr

52 nd altered ultrastructure in comparison with nontreated cells, whereas copper overload has the opposi

53 tors on rapamycin-treated HuH7 cells than on nontreated cells, with no affect on the level of surface

54 reporter gene activity was still present in nontreated cells.

55 ranscripts to approximately 13% of levels in nontreated cells.

56 d EGFR kinase activity to levels observed in nontreated cells.

57 as not significantly different from that for nontreated cells.

58 lacZ expression to less than 25% of that of nontreated cells.

59 is, and viral RNA accumulation compared with nontreated cells.

60 t blunting of mediator release compared with nontreated cells.

61 her uptake of (64)Cu-bis-DOTA-hypericin than nontreated cells.

62 lose/polyethylene terephthalate/glass fiber, nontreated/chemically treated) as well as possible trans

63 resulted in increased virus load compared to nontreated chickens.

64 experimental groups were evaluated: control (nontreated) clots, clots treated with pulsed high-intens

65 When compared with a nontreated cohort, OLT recipients receiving combination

66 enzyl applications at 1/100x compared to the nontreated control (23 g plant-1).

67 n grain yield, respectively, compared to the nontreated control (3063 kg ha-1).

68 y 25% and 18%, respectively, compared to the nontreated control (n = 338).

69 y 31% and 27%, respectively, compared to the nontreated control (n = 373).

70 vival of xenografted mice in comparison with nontreated control animals, but the effects were less pr

71 8-20, pair-fed dams injected with saline, or nontreated control dams.

72 ochloride daily on gestational Days 8-20 and nontreated control dams.

73 A nontreated control group of eligible patients was also s

74 dine or PBS treatment when compared with the nontreated control group.

75 5.83%, P=0.035) hearts compared with that in nontreated control hearts (84.85%).

76 increased its local population compared with nontreated control muscles.

77 median grade, 1.0; IQR, 0-2.0) compared with nontreated control patients (9% of patients with high BP

78 ted with a probiotic mixture compared to the nontreated control.

79 njured, nontreated controls (sham), injured, nontreated controls (control), or injured animals treate

80 and markedly reduced mortality compared with nontreated controls (four of five animals survived in a

81 compared with 7.0% (92 of 1306 patients) in nontreated controls (risk ratio, 0.48; 95% CI, 0.30-0.80

82 imals were allocated to either sham-injured, nontreated controls (sham), injured, nontreated controls

83 tiangiogenic drugs alone survived, while all nontreated controls and tumor vaccine-treated rats died

84 rotective effect against IRI compared with a nontreated controls for all analyzed intervention pathwa

85 gnificant increase in survival compared with nontreated controls was noted (maximum tolerated dose no

86 Intubated sham control and nontreated controls were included.

87 ed GBS vaginal colonization in comparison to nontreated controls, and this effect was partially depen

88 PGE(2), compared with nontreated controls, increased expression and activity (

89 cantly reduced tumor volume in comparison to nontreated controls, increased survival, and prevented t

90 recA was upregulated 20-40% compared to the nontreated controls, indicating that this component of t

91 nesis with a fourfold increase compared with nontreated controls.

92 umor volume was calculated and compared with nontreated controls.

93 ease in tumor growth rate in comparison with nontreated controls.

94 that was comparable with that of tumor-free nontreated controls.

95 d hypertrophic by treatment with PHE than in nontreated controls.

96 roups: treatment with ranolazine, GS-967, or nontreated controls.

97 nly detected after NGF treatment, but not in nontreated controls.

98 itment in the treated recipients relative to nontreated controls.

99 le their diffusion was completely blocked in nontreated controls.

100 failed to produce IL-10 compared with their nontreated counterparts.

101 e treated diabetic animals compared with the nontreated diabetic controls.

102 ated diabetic PB-MNCs versus those receiving nontreated diabetic PB-MNCs.

103 on, which was increased two-fold compared to nontreated diabetic rats.

104 ited significantly greater SGC survival than nontreated ears.

105 tion, we compared oxygen-deprived embryos to nontreated embryos in both wild-type and hif-1 mutants.

106 ctors or tumor cells induced angiogenesis in nontreated embryos, further indicating a direct proangio

107 ter PEX end between caplacizumab-treated and nontreated episodes (median [interquartile range], 14.5

108 visual acuity of 20/800 or better in fellow, nontreated eye were included.

109 different between treated eyes (n = 19) and nontreated eyes (n = 7, P = 0.3).

110 e ablation with 0.02% MMC were compared with nontreated eyes at Vissum Santa Hortensia, Madrid, Spain

111 er RLB, aqueous humor samples harvested from nontreated eyes but not from either the burned or the co

112 d signs of inflammation compared with fellow nontreated eyes in patients with nAMD.

113 ulated by the comparison between treated and nontreated eyes in the same mouse.

114 ng ability was measured at two visits in 124 nontreated eyes of 124 patients with AMD, who were enrol

115 s was observed on edges of human TM beams in nontreated eyes, with intense staining in the juxtacanal

116 or IOP were detected between IPH-treated and nontreated eyes.

117 Control data were obtained from the nontreated fellow eyes, 24 normal monkeys, and 19 monkey

118 Posttreatment ADC values for nontreated fibroid tissue (1685 mm(-6)/sec2 +/- 468) dif

119 months were compared with volume changes in nontreated fibroids and with MR-based thermal dose estim

120 ced mobility by SDS-PAGE compared to that of nontreated filaments.

121 eater viability than B cells cocultured with nontreated FLS.

122 come versus 255 of 422 patients (63%) in the nontreated group (p < 0.001).

123 wer subbasal nerves number compared with the nontreated group (P = 0.01).

124 roup and 0.032 episodes/patient-month in the nontreated group (p = 0.04).

125 roup and 0.012 episodes/patient-month in the nontreated group (p = 0.05).

126 roup and 0.035 episodes/patient-month in the nontreated group (p = 0.56).

127 roup and 0.029 episodes/patient-month in the nontreated group (p = 0.64).

128 group and 67% and 41 %, respectively, in the nontreated group (p = 0.77).

129 choroidal thickness than the patients in the nontreated group after adjusting for age, axial length,

130 The nontreated group exhibited persistent endogenous glucose

131 and 73 (65%) received no additional therapy (nontreated group).

132 ssed ROP who had not received any treatment (nontreated group).

133 d animals viral load was 2.58 +/- 1.0 in the nontreated group, 4.74 +/- 1.38 in the group treated wit

134 ues during the endotoxic phase (P < 0.05 vs. nontreated group, ANOVA).

135 O2 (140% and 79%, respectively; P < 0.05 vs. nontreated group, ANOVA).

136 remained within baseline range (P < 0.05 vs. nontreated group, ANOVA).

137 and GC were markedly lower compared with the nontreated group.

138 ficantly lower incidence of infection in the nontreated group.

139 in the treated group and 17.8 months in the nontreated group.

140 used to achieve comparability of treated and nontreated groups in terms of their observed covariates

141 genation group, whereas the sham-treated and nontreated groups showed retinal thinning and choroidal

142 NV in the ribavirin-treated (100 microM) and nontreated groups showed that the mutation rates were si

143 mol/mL and < 6.0 mumol/mL in the treated and nontreated groups, respectively) and reduced tPA levels

144 Four nontreated healthy rats served as controls.

145 p analysis of mRNA from IL-1beta-treated and nontreated HS-27a cells has identified some candidate mo

146 ntent (0.79 +/- 0.05 mumol/g, P < .01 versus nontreated hypercholesterolemic rabbits), restored the v

147 duced upregulation of CD63 on basophils from nontreated individuals with birch pollen-related apple a

148 postinfection (p.i.) compared to results for nontreated, infected mice.

149 Control mice were transplanted with nontreated islets and were injected with saline.

150 Compared with nontreated islets, the combination of KIC/glutamine (10/

151 the relative (ratio of treated kidney value/nontreated kidney value) clearance of small- and large-m

152 Biopsies at BT-treated and nontreated locations were analyzed by histological and i

153 formed in 16 hormone-treated patients and 48 nontreated matched control patients before radical prost

154 in brain was found in comparison to that in nontreated mice (n = 3, P < 0.05).

155 nificantly (P = .0001) compared with that in nontreated mice and correlated well with ex vivo P-selec

156 significantly different between treated and nontreated mice at any time.

157 Molecular imaging in nontreated mice detected a 2-fold increase in P-selectin

158 same number of splenic dendritic cells from nontreated mice did not confer resistance to burn wound

159 All nontreated mice died, with a median survival of 16 d.

160 Unlike F4/80(+) APCs from nontreated mice, F4/80(+) APCs from RLB mice were unable

161 plasmic localization of CAR in the livers of nontreated mice, indicating that CAR translocates into n

162 oke, in mice subjected to osmotherapy and in nontreated mice.

163 ptake of (64)Cu-ATSM by tumors compared with nontreated mice.

164 ntly higher (18)F-FDOPA uptake than those in nontreated mice.

165 ur after the last AP challenge compared with nontreated mice.

166 nt and increased survival by 40% compared to nontreated mice.

167 gastric H. pylori colonization compared with nontreated mice.

168 rom treated microchimeric mice compared with nontreated microchimeric or with treated nonmicrochimeri

169 rval [CI], 1%-25%) and 16 of 37 infants with nontreated mothers (43%; 95% CI, 27%-59%) presented with

170 eated mothers did not differ from fetuses of nontreated mothers according to mother's age, gestationa

171 profoundly reduced angiogenin expression in nontreated murine chronic diabetic wounds.

172 nal length in (+)-pentazocine-treated versus nontreated mutant mice.

173 Suspensions of treated and nontreated mycobacteria could be easily differentiated a

174 vided into five groups: sham, noninjured and nontreated (n = 6); control, injured and aerosolized wit

175 ed into two trauma groups, treated (N=7) and nontreated (N=8) animals.

176 d into three study groups: sham (noninjured, nontreated, n = 6); control (injured, treated with salin

177 ntrast to intermediate inhibitory effects in nontreated neutrophils, T. gondii induced a complete blo

178 TFII-I remains predominantly nuclear in both nontreated NIH 3T3 cells and cells treated with thapsiga

179 se tolerance tests (compared with those of 7 nontreated, nontransplanted mice with streptozotocin-ind

180 only observed in diseased mice, but also in nontreated NSG controls.

181 BD rats were assigned to MCC950-treated or nontreated (NT) groups.

182 de (1 muM) increased I(Kv11.1) compared with nontreated or acutely treated cells.

183 ore IL-2 and IFN-gamma than lymphocytes from nontreated or control-peptide-treated mice upon restimul

184 ability of 1,25-dihydroxyvitamin D3-treated, nontreated, or cyclosporine (CsA)-treated mice to resist

185 onchial inflammation score (P < 0.0001) than nontreated OVA-obese mice.

186 61 +/- 2 vs. 145 +/- 7 mg/dl, treated versus nontreated; P < 0.0001) and lowered islet TAG content (3

187 .7 vs. 47.8 +/- 2.7 ng/islet, treated versus nontreated; P < 0.0001) and preserved insulin mRNA level

188 +/- 16 vs. 388 +/- 36 mg/dl, treated versus nontreated; P < 0.0001) but did not prevent the rise in

189 (2); P = 0.001), whereas the function of the nontreated part increased (HBS-pre, 1.4%/min/m(2); HBS-p

190 function change was smaller (+/-6.0%) in the nontreated part of the liver, but limits of agreement we

191 atients were anticoagulated acutely, and the nontreated patient had recurrent, probably thromboemboli

192 ite treatment and one recurrent embolus in a nontreated patient.

193 in aspirin-treated diabetic patients versus nontreated patients (P < 0.001).

194 ulants was 13.6, in comparison with 27.3 for nontreated patients and 25.7 for patients receiving anti

195 agulants was 8.0, in comparison with 8.6 for nontreated patients and 5.3 for patients receiving antip

196 Ag seroclearance was durable for treated and nontreated patients and lasted, on average, over 13 year

197 the CD4(+)CD90(+)/regulatory T cell ratio in nontreated patients compared with treated patients and h

198 Treated patients were less likely than nontreated patients to receive mechanical ventilation af

199 baseline creatinine (mg/dl) for treated and nontreated patients was 1.3 +/- 0.24 and 1.0 +/- 0.25, r

200 At 24 wk, creatinine of treated and nontreated patients was 1.5 +/- 0.34 and 4.9 +/- 2.4 (P

201 rine protein excretion (g/d) for treated and nontreated patients was 1.6 +/- 0.68 and 0.78 +/- 0.39,

202 Average baseline creatinine for treated and nontreated patients was 1.7 +/- 0.46 and 1.9 +/- 0.42, r

203 At 12 wk, creatinine for treated and nontreated patients was 2.0 +/- 1.0 and 9.2 +/- 2.0 (P =

204 eline 24-h protein excretion for treated and nontreated patients was 5.4 +/- 1.6 and 5.2 +/- 0.97 (P

205 ed patients who did not make antibody and in nontreated patients who did make antibody (6.0% vs. 5.7%

206 ured by enzyme-linked immunosorbent assay in nontreated patients with HeFH carrying a D206E (n = 237)

207 in the former group between ALP treated and nontreated patients.

208 rate of CVS progression between treated and nontreated patients.

209 ted and 1.2 years (range, 0.9-8.8 years) for nontreated patients.

210 accuracy in localizing prostate cancer as in nontreated patients.

211 aily for a minimum of 2 yr as compared to 17 nontreated patients.

212 between the sorafenib-treated groups and the nontreated patients.

213 Among the nontreated, patients with an SUD had a significantly hig

214 Finally, we analyzed docetaxel-treated and nontreated PC3 cells to reveal proteome changes at the s

215 e entire 70-day period of the study, whereas nontreated Pcp animals die 40-60 days after initiation o

216 3-6 months after medication start following nontreated periods.

217 Treated and nontreated populations were similar in terms of race, et

218 lessened the rise in plasma TAG observed in nontreated rats (239 +/- 16 vs. 388 +/- 36 mg/dl, treate

219 erved morphological appearance than those in nontreated rats, as observed at different survival times

220 s 7 and 14 days postinjury, as compared with nontreated rats.

221 f survival (5.6+/-0.8 days) as compared with nontreated recipients (2.4+/-0.5 days).

222 n general low (2.5% and 2.0% for treated and nontreated, respectively) and similar across estimated g

223 rescence emission was checked in treated and nontreated samples of all the species, whereas histochem

224 qs quorum sensing antagonists in treated and nontreated samples suggests suppression of phenazine pro

225 e) that distinguished IL-6-stimulated versus nontreated samples.

226 ), whereas revascularized (0.5 +/- 0.21) and nontreated segments (-0.07 +/- 0.34) demonstrated noncon

227 Nontreated, sham and naive rats were also included.

228 Comparing treated and nontreated sides of the brain in 3 patients who underwen

229 >80%) compared with signals of contralateral nontreated sites at 4 h and at 1 d after PIT.

230 in the field sludge-amended soil compared to nontreated soil (32 versus 11 ng/g d.w.), and higher con

231 ms living in sludge-amended soil compared to nontreated soil (566 versus 103 ng/g d.w.) were observed

232 By flow cytometry, formalin-treated and nontreated spores of Encephalitozoon were identified to

233 n the most intense peaks of fluorescence for nontreated spores.

234 strategy, comparing outcomes for treated and nontreated students before and after the introduction of

235 inical trials have shown that, compared with nontreated subjects, rHuEPO-treated ICU patients will ha

236 We also studied recipients of nontreated syngenetic grafts.

237 nt with HRG compared to its level in control nontreated T47D cells.

238 ed Ca(2+) transients and decay compared with nontreated TAC hearts.

239 As compared to a frozen nontreated tissue sample, the liposome preparation proto

240 t upregulation of PIM1 as compared with bulk nontreated tumor cells.

241 225 (9.84 +/- 2.51 %ID/g; P = 0.029) than in nontreated tumors (6.14 +/- 0.67 %ID/g), resulting in en

242 stoperative staging classifications used for nontreated tumors may not accurately predict patient pro

243 from both TRAIL receptor agonist-treated and nontreated tumors were found to be resistant to TRAIL-in

244 ition, exerts a robust effect in treated and nontreated tumors, indicative of a systemic antitumoral

245 no significant changes were demonstrated in nontreated tumors.

246 as 0.75 (95% confidence interval, 0.71-0.79; nontreated used as reference).

247 ve statistics were obtained from treated and nontreated uterine tissue before and after treatment and

248 atment, 870.7 cm(3); P = 0.003), whereas the nontreated volume increased (pretreatment, 412.7 cm(3);

249 betaAR antagonist metoprolol (CSQ/betaARKct nontreated vs. CSQ/betaARKct metoprolol treated, 15 +/-

250 2 wk, 24-h protein excretion for treated and nontreated was 2.8 +/- 1.0 and 10.5 +/- 3.5 (P = 0.008).

251 ients (mean age 67 years; 44% women) treated/nontreated with statins.

252 in stromal cell proliferation compared with nontreated wounds, and a 2.5-fold increase compared with

253 5.6 to 9.5 days earlier than PRP-treated and nontreated wounds, respectively.

254 ecreased in the rosiglitazone-treated versus nontreated ZA sites 5 wk after EPD.